Global Sickle Cell Anemia Therapeutics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Global Sickle Cell Anemia Therapeutics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Sickle Cell Anemia Therapeutics market size was valued at US$ 4027 million in 2024 and is forecast to a readjusted size of USD 10820 million by 2031 with a CAGR of 15.3% during review period.

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.

Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.

In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.

This report is a detailed and comprehensive analysis for global Sickle Cell Anemia Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Sickle Cell Anemia Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031

Global Sickle Cell Anemia Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Sickle Cell Anemia Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Sickle Cell Anemia Therapeutics market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Sickle Cell Anemia Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Sickle Cell Anemia Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, Pfizer, Novartis, Global Blood Therapeutics, Micelle BioPharma, Bluebird Bio, Prolong Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Sickle Cell Anemia Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Blood Transfusion

Pharmacotherapy

Bone Marrow Transplant

Market segment by Application

Child

Adult

Market segment by players, this report covers

Emmaus Medical

Addmedica

Gamida Cell

GlycoMimetics

Pfizer

Novartis

Global Blood Therapeutics

Micelle BioPharma

Bluebird Bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo Biosciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Sickle Cell Anemia Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Sickle Cell Anemia Therapeutics, with revenue, gross margin, and global market share of Sickle Cell Anemia Therapeutics from 2020 to 2025.

Chapter 3, the Sickle Cell Anemia Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Sickle Cell Anemia Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Sickle Cell Anemia Therapeutics.

Chapter 13, to describe Sickle Cell Anemia Therapeutics research findings and conclusion.